Moderna publishes interim results from older adults in phase 1 study of its COVID-19 vaccine EP News Bureau Sep 30, 2020 At the 25 µg and 100 µg dose levels, mRNA-1273 was generally well-tolerated in all age cohorts, neutralizing antibody titers and T…
